| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 6 Feb 2025 | 3 Feb 2025 |
| MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve unaudited financial results for the quarter ended December 31 2024. Please find attached results and LLR - Q3 FY 25 (As Per BSE Announcement dated on 06.02.2025) | ||
| Board Meeting | 14 Jan 2025 | 14 Jan 2025 |
| Please find attached outcome of Board Meeting. | ||
| Board Meeting | 11 Nov 2024 | 6 Nov 2024 |
| MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2024 inter alia to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended on September 30 2024. Please find attached results and LLR - Q2 FY 25 (As Per BSE Announcement Dated on 11.11.2024) | ||
| Board Meeting | 27 Aug 2024 | 27 Aug 2024 |
| Please find enclosed letter comprising outcome of board meeting held on 27-August-2024. Please find enclosed update on disclosure submitted on August 27, 2024. (As per BSE Announcement Dated on 14/10/2024) | ||
| Board Meeting | 12 Aug 2024 | 7 Aug 2024 |
| MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended we hereby inform that a meeting of the Board of Directors of the Company is scheduled to be held on Monday 12th August 2024 inter-alia to consider and approve the following items: a. Un-audited standalone and consolidated financial results for the quarter ended 30th June 2024. b. Declaration of dividend for the financial year 2023-24. c. The record date for the declaration of dividend for the financial year 2023-24. Purpose of the meeting has been revised The company hereby recalls the items (b) above, i.e., proposal of declaration of final dividend for the financial year 2023-24 as the same was not placed before the Board of Directors while the approving annual financial statement for the financial 2023-24, in their meeting held on 21st May 2024; and (c) the record date. Kindly accept our sincere apologies for the inconvenience caused. Subject: Intimation of Board Meeting dated 7th August 2024 - Rectification Dear Sir/Maam, Reference is invited to our intimation letter dated 7th August 2024 wherein it was informed that a meeting of Board of Directors of the company is scheduled to be held on Monday, 12th August 2024, inter-alia, to consider and approve (a) the unaudited standalone and consolidated financial results of the company for the quarter ended 30th June 2024, (b) declaration of final dividend for the financial year 2023-24 and; (c) record date. The company hereby recalls the items (b) above, i.e., proposal of declaration of final dividend for the financial year 2023-24 as the same was not placed before the Board of Directors while the approving annual financial statement for the financial 2023-24, in their meeting held on 21st May 2024; and (c) the record date. Kindly accept our sincere apologies for the inconvenience caused. (As Per BSE Announcement dated on 08.08.2024) Please find enclsoed results for the Q1 FY 25. (As Per BSE Announcement Dated on 12.08.2024) | ||
| Board Meeting | 21 May 2024 | 14 May 2024 |
| MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 inter alia to consider and approve standalone and consolidated audited financial results for the quarter and financial year ended 31st March 2024. Please find enclosed audited Standalone and consolidated financial results - Q4-FY24 (As Per BSE Announcement Dated on 21/05/2024) | ||
With this approval, Morepen Laboratories aims to strengthen its presence in China, which is one of the world’s largest pharmaceutical markets.
Developed from scratch, this drug offers an inexpensive and superior alternative to current treatments, making it accessible to hundreds of millions of patients.
Here are some of the stocks that may see significant price movement today: Tata Motors, ITC, Kalyan Jewellers, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
